- In late July and early August 2026, Hims & Hers Health was sued by the Federal Trade Commission over alleged deceptive subscription practices and misuse of sensitive health data, while the company publicly rejected the claims and defended its telehealth and privacy standards.
- A few days later, Hims & Hers rolled out an AI-powered weight loss care experience for Hers members, including a connected smart scale, signaling a push toward more integrated, data-rich virtual care.
- We’ll now examine how the FTC lawsuit and AI-driven weight loss launch might reshape Hims & Hers Health’s investment narrative.
Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
Hims & Hers Health Investment Narrative Recap
To own Hims & Hers Health, you need to believe in its ability to convert digital, subscription-based telehealth into durable revenue while managing rising regulatory scrutiny. Right now, the FTC lawsuit around subscriptions and health data sits alongside weight loss as a key near term swing factor, with regulatory outcomes and consumer trust potentially affecting growth and marketing efficiency. The news is material because it directly targets the company’s data practices at the same time its model is becoming more data intensive.
The AI powered Hers weight loss experience, with its smart scale and tightly integrated app, is the announcement most connected to this moment. It leans into richer data and personalization, which lines up with current growth catalysts in GLP 1 weight loss and AI driven care, but also intersects with the core concern of regulators around how sensitive health information is collected, stored, and used. How well Hims & Hers aligns this new product with evolving rules will be critical.
Yet behind the product story, there is a separate risk investors should be aware of around how tighter data privacy rules and the FTC case could eventually reshape...
Read the full narrative on Hims & Hers Health (it's free!)
Hims & Hers Health's narrative projects $5.6 billion revenue and $211.5 million earnings by 2029. This requires 33.0% yearly revenue growth and a $224.7 million earnings increase from -$13.2 million today.
Uncover how Hims & Hers Health's forecasts yield a $28.42 fair value, a 10% downside to its current price.
Exploring Other Perspectives
Some of the lowest ranked analysts were already cautious, assuming revenue of about US$5.9 billion and earnings of roughly US$235.7 million by 2029, and the FTC action plus data privacy pressure may reinforce their more pessimistic view compared with investors who see AI driven care as a long term catalyst.
Explore 25 other fair value estimates on Hims & Hers Health - why the stock might be worth 26% less than the current price!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Hims & Hers Health research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Hims & Hers Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Hims & Hers Health's overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
- This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
- Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
- AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com